The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Mucopolysaccharidosis II Market Research Report 2024
Synopsis
The global Mucopolysaccharidosis II market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Mucopolysaccharidosis II is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Mucopolysaccharidosis II is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Mucopolysaccharidosis II include Alexion Pharmaceuticals, Inc., AngioChem Inc., ArmaGen Inc., Bioasis Technologies Inc., Green Cross Corporation, Inventiva, JCR Pharmaceuticals Co., Ltd., Laboratorios Del Dr. Esteve S.A. and RegenxBio Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Mucopolysaccharidosis II, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mucopolysaccharidosis II.
Report Scope
The Mucopolysaccharidosis II market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Mucopolysaccharidosis II market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mucopolysaccharidosis II manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alexion Pharmaceuticals, Inc.
AngioChem Inc.
ArmaGen Inc.
Bioasis Technologies Inc.
Green Cross Corporation
Inventiva
JCR Pharmaceuticals Co., Ltd.
Laboratorios Del Dr. Esteve S.A.
RegenxBio Inc.
Sangamo BioSciences, Inc.
Takeda
Segment by Type
JR-141
EGT-301
DUOC-01
AGT-182
JR-032
Others
Segment by Application
Hospital
Clinic
Research Center
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Mucopolysaccharidosis II manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Mucopolysaccharidosis II in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Mucopolysaccharidosis II market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Mucopolysaccharidosis II is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Mucopolysaccharidosis II is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Mucopolysaccharidosis II include Alexion Pharmaceuticals, Inc., AngioChem Inc., ArmaGen Inc., Bioasis Technologies Inc., Green Cross Corporation, Inventiva, JCR Pharmaceuticals Co., Ltd., Laboratorios Del Dr. Esteve S.A. and RegenxBio Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Mucopolysaccharidosis II, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mucopolysaccharidosis II.
Report Scope
The Mucopolysaccharidosis II market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Mucopolysaccharidosis II market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mucopolysaccharidosis II manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alexion Pharmaceuticals, Inc.
AngioChem Inc.
ArmaGen Inc.
Bioasis Technologies Inc.
Green Cross Corporation
Inventiva
JCR Pharmaceuticals Co., Ltd.
Laboratorios Del Dr. Esteve S.A.
RegenxBio Inc.
Sangamo BioSciences, Inc.
Takeda
Segment by Type
JR-141
EGT-301
DUOC-01
AGT-182
JR-032
Others
Segment by Application
Hospital
Clinic
Research Center
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Mucopolysaccharidosis II manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Mucopolysaccharidosis II in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Mucopolysaccharidosis II Market Overview
1.1 Product Overview and Scope of Mucopolysaccharidosis II
1.2 Mucopolysaccharidosis II Segment by Type
1.2.1 Global Mucopolysaccharidosis II Market Value Comparison by Type (2024-2030)
1.2.2 JR-141
1.2.3 EGT-301
1.2.4 DUOC-01
1.2.5 AGT-182
1.2.6 JR-032
1.2.7 Others
1.3 Mucopolysaccharidosis II Segment by Application
1.3.1 Global Mucopolysaccharidosis II Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Center
1.3.5 Others
1.4 Global Mucopolysaccharidosis II Market Size Estimates and Forecasts
1.4.1 Global Mucopolysaccharidosis II Revenue 2019-2030
1.4.2 Global Mucopolysaccharidosis II Sales 2019-2030
1.4.3 Global Mucopolysaccharidosis II Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Mucopolysaccharidosis II Market Competition by Manufacturers
2.1 Global Mucopolysaccharidosis II Sales Market Share by Manufacturers (2019-2024)
2.2 Global Mucopolysaccharidosis II Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Mucopolysaccharidosis II Average Price by Manufacturers (2019-2024)
2.4 Global Mucopolysaccharidosis II Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Mucopolysaccharidosis II, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Mucopolysaccharidosis II, Product Type & Application
2.7 Mucopolysaccharidosis II Market Competitive Situation and Trends
2.7.1 Mucopolysaccharidosis II Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Mucopolysaccharidosis II Players Market Share by Revenue
2.7.3 Global Mucopolysaccharidosis II Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Mucopolysaccharidosis II Retrospective Market Scenario by Region
3.1 Global Mucopolysaccharidosis II Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Mucopolysaccharidosis II Global Mucopolysaccharidosis II Sales by Region: 2019-2030
3.2.1 Global Mucopolysaccharidosis II Sales by Region: 2019-2024
3.2.2 Global Mucopolysaccharidosis II Sales by Region: 2025-2030
3.3 Global Mucopolysaccharidosis II Global Mucopolysaccharidosis II Revenue by Region: 2019-2030
3.3.1 Global Mucopolysaccharidosis II Revenue by Region: 2019-2024
3.3.2 Global Mucopolysaccharidosis II Revenue by Region: 2025-2030
3.4 North America Mucopolysaccharidosis II Market Facts & Figures by Country
3.4.1 North America Mucopolysaccharidosis II Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Mucopolysaccharidosis II Sales by Country (2019-2030)
3.4.3 North America Mucopolysaccharidosis II Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Mucopolysaccharidosis II Market Facts & Figures by Country
3.5.1 Europe Mucopolysaccharidosis II Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Mucopolysaccharidosis II Sales by Country (2019-2030)
3.5.3 Europe Mucopolysaccharidosis II Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Mucopolysaccharidosis II Market Facts & Figures by Country
3.6.1 Asia Pacific Mucopolysaccharidosis II Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Mucopolysaccharidosis II Sales by Country (2019-2030)
3.6.3 Asia Pacific Mucopolysaccharidosis II Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Mucopolysaccharidosis II Market Facts & Figures by Country
3.7.1 Latin America Mucopolysaccharidosis II Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Mucopolysaccharidosis II Sales by Country (2019-2030)
3.7.3 Latin America Mucopolysaccharidosis II Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Mucopolysaccharidosis II Market Facts & Figures by Country
3.8.1 Middle East and Africa Mucopolysaccharidosis II Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Mucopolysaccharidosis II Sales by Country (2019-2030)
3.8.3 Middle East and Africa Mucopolysaccharidosis II Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Mucopolysaccharidosis II Sales by Type (2019-2030)
4.1.1 Global Mucopolysaccharidosis II Sales by Type (2019-2024)
4.1.2 Global Mucopolysaccharidosis II Sales by Type (2025-2030)
4.1.3 Global Mucopolysaccharidosis II Sales Market Share by Type (2019-2030)
4.2 Global Mucopolysaccharidosis II Revenue by Type (2019-2030)
4.2.1 Global Mucopolysaccharidosis II Revenue by Type (2019-2024)
4.2.2 Global Mucopolysaccharidosis II Revenue by Type (2025-2030)
4.2.3 Global Mucopolysaccharidosis II Revenue Market Share by Type (2019-2030)
4.3 Global Mucopolysaccharidosis II Price by Type (2019-2030)
5 Segment by Application
5.1 Global Mucopolysaccharidosis II Sales by Application (2019-2030)
5.1.1 Global Mucopolysaccharidosis II Sales by Application (2019-2024)
5.1.2 Global Mucopolysaccharidosis II Sales by Application (2025-2030)
5.1.3 Global Mucopolysaccharidosis II Sales Market Share by Application (2019-2030)
5.2 Global Mucopolysaccharidosis II Revenue by Application (2019-2030)
5.2.1 Global Mucopolysaccharidosis II Revenue by Application (2019-2024)
5.2.2 Global Mucopolysaccharidosis II Revenue by Application (2025-2030)
5.2.3 Global Mucopolysaccharidosis II Revenue Market Share by Application (2019-2030)
5.3 Global Mucopolysaccharidosis II Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Alexion Pharmaceuticals, Inc.
6.1.1 Alexion Pharmaceuticals, Inc. Corporation Information
6.1.2 Alexion Pharmaceuticals, Inc. Description and Business Overview
6.1.3 Alexion Pharmaceuticals, Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Alexion Pharmaceuticals, Inc. Mucopolysaccharidosis II Product Portfolio
6.1.5 Alexion Pharmaceuticals, Inc. Recent Developments/Updates
6.2 AngioChem Inc.
6.2.1 AngioChem Inc. Corporation Information
6.2.2 AngioChem Inc. Description and Business Overview
6.2.3 AngioChem Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AngioChem Inc. Mucopolysaccharidosis II Product Portfolio
6.2.5 AngioChem Inc. Recent Developments/Updates
6.3 ArmaGen Inc.
6.3.1 ArmaGen Inc. Corporation Information
6.3.2 ArmaGen Inc. Description and Business Overview
6.3.3 ArmaGen Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.3.4 ArmaGen Inc. Mucopolysaccharidosis II Product Portfolio
6.3.5 ArmaGen Inc. Recent Developments/Updates
6.4 Bioasis Technologies Inc.
6.4.1 Bioasis Technologies Inc. Corporation Information
6.4.2 Bioasis Technologies Inc. Description and Business Overview
6.4.3 Bioasis Technologies Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bioasis Technologies Inc. Mucopolysaccharidosis II Product Portfolio
6.4.5 Bioasis Technologies Inc. Recent Developments/Updates
6.5 Green Cross Corporation
6.5.1 Green Cross Corporation Corporation Information
6.5.2 Green Cross Corporation Description and Business Overview
6.5.3 Green Cross Corporation Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Green Cross Corporation Mucopolysaccharidosis II Product Portfolio
6.5.5 Green Cross Corporation Recent Developments/Updates
6.6 Inventiva
6.6.1 Inventiva Corporation Information
6.6.2 Inventiva Description and Business Overview
6.6.3 Inventiva Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Inventiva Mucopolysaccharidosis II Product Portfolio
6.6.5 Inventiva Recent Developments/Updates
6.7 JCR Pharmaceuticals Co., Ltd.
6.6.1 JCR Pharmaceuticals Co., Ltd. Corporation Information
6.6.2 JCR Pharmaceuticals Co., Ltd. Description and Business Overview
6.6.3 JCR Pharmaceuticals Co., Ltd. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.4.4 JCR Pharmaceuticals Co., Ltd. Mucopolysaccharidosis II Product Portfolio
6.7.5 JCR Pharmaceuticals Co., Ltd. Recent Developments/Updates
6.8 Laboratorios Del Dr. Esteve S.A.
6.8.1 Laboratorios Del Dr. Esteve S.A. Corporation Information
6.8.2 Laboratorios Del Dr. Esteve S.A. Description and Business Overview
6.8.3 Laboratorios Del Dr. Esteve S.A. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Laboratorios Del Dr. Esteve S.A. Mucopolysaccharidosis II Product Portfolio
6.8.5 Laboratorios Del Dr. Esteve S.A. Recent Developments/Updates
6.9 RegenxBio Inc.
6.9.1 RegenxBio Inc. Corporation Information
6.9.2 RegenxBio Inc. Description and Business Overview
6.9.3 RegenxBio Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.9.4 RegenxBio Inc. Mucopolysaccharidosis II Product Portfolio
6.9.5 RegenxBio Inc. Recent Developments/Updates
6.10 Sangamo BioSciences, Inc.
6.10.1 Sangamo BioSciences, Inc. Corporation Information
6.10.2 Sangamo BioSciences, Inc. Description and Business Overview
6.10.3 Sangamo BioSciences, Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sangamo BioSciences, Inc. Mucopolysaccharidosis II Product Portfolio
6.10.5 Sangamo BioSciences, Inc. Recent Developments/Updates
6.11 Takeda
6.11.1 Takeda Corporation Information
6.11.2 Takeda Mucopolysaccharidosis II Description and Business Overview
6.11.3 Takeda Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Takeda Mucopolysaccharidosis II Product Portfolio
6.11.5 Takeda Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Mucopolysaccharidosis II Industry Chain Analysis
7.2 Mucopolysaccharidosis II Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Mucopolysaccharidosis II Production Mode & Process
7.4 Mucopolysaccharidosis II Sales and Marketing
7.4.1 Mucopolysaccharidosis II Sales Channels
7.4.2 Mucopolysaccharidosis II Distributors
7.5 Mucopolysaccharidosis II Customers
8 Mucopolysaccharidosis II Market Dynamics
8.1 Mucopolysaccharidosis II Industry Trends
8.2 Mucopolysaccharidosis II Market Drivers
8.3 Mucopolysaccharidosis II Market Challenges
8.4 Mucopolysaccharidosis II Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
